Literature DB >> 25449512

Incidence and predictors of appropriate therapies delivered by the implantable cardioverter defibrillator in patients with ischemic cardiomyopathy: a systematic review.

Junève Gracieux1, Gillian D Sanders1, Sean D Pokorney2, Renato D Lopes2, Kevin Thomas2, Sana M Al-Khatib3.   

Abstract

BACKGROUND: Although the implantable cardioverter defibrillator (ICD) improves the survival of patients at increased risk of sudden cardiac death due to systolic heart failure, ICD shocks have been associated with both worse survival and quality of life. We performed a systematic review of primary prevention ICD studies to evaluate the incidence and clinical predictors of appropriate ICD shocks or anti-tachycardia pacing (ATP) in patients with ischemic cardiomyopathy.
METHODS: We performed a literature search in MEDLINE. Eligible studies had to be full text, written in the English language, performed in adults aged ≥ 19, and published from 1999 through April 2014.
RESULTS: Of 289 identified studies, 9 met all our inclusion criteria. The mean length of follow up ranged from 17 to 45.5 months. The incidence of appropriate ICD therapy varied from 17% to 31%. Among those studies, only 4 included data on the clinical characteristics of appropriate ICD therapy recipients. Characteristics associated with appropriate ICD therapy included male sex, advanced New York Heart Association class, non-sustained ventricular tachycardia, and lower serum creatinine. Patients who received appropriate therapy were also less likely to be on a beta-blocker. Left ventricular ejection fraction was not significantly different between patients who received appropriate ICD therapy and those who did not.
CONCLUSION: The incidence of appropriate ICD therapy is not trivial in patients with ischemic cardiomyopathy and a primary prevention ICD. Predictors of appropriate ICD therapy have not been adequately assessed in large patient populations. As such, large prospective studies of predictors of appropriate ICD therapies are needed.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Appropriate implantable cardioverter defibrillator therapies; Implantable cardioverter defibrillator; Incidence; Predictors; Systematic review

Mesh:

Year:  2014        PMID: 25449512     DOI: 10.1016/j.ijcard.2014.09.170

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

1.  Implantable cardioverter-defibrillator elective generator replacement: a procedure for all?

Authors:  Sergio Barra; Manoj Goonewardene; Patrick Heck; David Begley; Munmohan Virdee; Simon Fynn; Andrew Grace; Sharad Agarwal
Journal:  J Interv Card Electrophysiol       Date:  2016-01-12       Impact factor: 1.900

2.  Predicting appropriate shocks in patients with heart failure: Patient level meta-analysis from SCD-HeFT and MADIT II.

Authors:  Emily P Zeitler; Sana M Al-Khatib; Daniel J Friedman; Joo Yoon Han; Jeanne E Poole; Gust H Bardy; J Thomas Bigger; Alfred E Buxton; Arthur J Moss; Kerry L Lee; Paul Dorian; Riccardo Cappato; Alan H Kadish; Peter J Kudenchuk; Daniel B Mark; Lurdes Y T Inoue; Gillian D Sanders
Journal:  J Cardiovasc Electrophysiol       Date:  2017-08-23

3.  Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction.

Authors:  Pieter Martens; Dieter Nuyens; Maximo Rivero-Ayerza; Hugo Van Herendael; Jan Vercammen; Wendy Ceyssens; Evert Luwel; Matthias Dupont; Wilfried Mullens
Journal:  Clin Res Cardiol       Date:  2019-02-20       Impact factor: 5.460

4.  Long-Term Outcome of Combined (Percutaneous Intramyocardial and Intracoronary) Application of Autologous Bone Marrow Mononuclear Cells Post Myocardial Infarction: The 5-Year MYSTAR Study.

Authors:  Mariann Gyöngyösi; Georgiana-Aura Giurgea; Bonni Syeda; Silvia Charwat; Beatrice Marzluf; Julia Mascherbauer; Andras Jakab; Abelina Zimba; Márta Sárközy; Noemi Pavo; Heinz Sochor; Senta Graf; Irene Lang; Gerald Maurer; Jutta Bergler-Klein
Journal:  PLoS One       Date:  2016-10-20       Impact factor: 3.240

5.  Effectiveness of Implantable Cardioverter-Defibrillator Therapy for Heart Failure Patients according to Ischemic or Non-Ischemic Etiology in Korea.

Authors:  Kyu-Hwan Park; Chan-Hee Lee; Byung Chun Jung; Yongkeun Cho; Myung Hwan Bae; Yoon-Nyun Kim; Hyoung-Seob Park; Seongwook Han; Young Soo Lee; Dae-Woo Hyun; Jun Kim; Dae Kyeong Kim; Tae-Jun Cha; Dong-Gu Shin
Journal:  Korean Circ J       Date:  2016-12-27       Impact factor: 3.243

6.  Practical applicability of landiolol, an ultra-short-acting β1-selective blocker, for rapid atrial and ventricular tachyarrhythmias with left ventricular dysfunction.

Authors:  Yuko Wada; Takeshi Aiba; Yasuyuki Tsujita; Hideki Itoh; Mitsuru Wada; Ikutaro Nakajima; Kohei Ishibashi; Hideo Okamura; Koji Miyamoto; Takashi Noda; Yasuo Sugano; Hideaki Kanzaki; Toshihisa Anzai; Kengo Kusano; Satoshi Yasuda; Minoru Horie; Hisao Ogawa
Journal:  J Arrhythm       Date:  2015-11-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.